Title:Current Perspectives of Matrix Metalloproteinase 11 (MMP11) as a Diagnostic
and Therapeutic Target for Cancer
Volume: 20
Issue: 3
Author(s): Asokan Shobana, Remella Venkata Deeksha, Syed Ali Abdul Rahman, Tiviya Thangaswamy, Revathi Paramasivam Oviya*Gopal Gopisetty
Affiliation:
- Department of Biotechnology, School of Bio and Chemical Engineering, Sathyabama Institute of Science and Technology,
Chennai, 600119, Tamil Nadu, India
Keywords:
MMPs, MMP11, diagnostic marker, prognostic marker, cancer immunotherapy, gene therapy.
Abstract: Matrix metalloproteinase 11 (MMP11), also known as stromelysin-3, is a member of the
matrix metalloproteinases family of proteins that are involved in physiological and pathological extracellular
matrix remodelling. MMP11 does not hydrolyse classical MMP substrates, such as laminin
and fibronectin, and many of its substrates remain unknown, piquing the interest of researchers. Several
studies have reported the role of MMP11 in inducing tumour growth by inhibiting apoptosis and
promoting cancer cell migration and invasion. Various reports have shown its potential as a diagnostic
and prognostic marker in a majority of cancers. MMP11 also induces an immune response as a
tumour-associated antigen, and recent evidence shows the involvement of many microRNAs in targeting
MMP11 in cancer, with prospective future applications in cancer immunotherapy and gene
silencing. Owing to the importance of MMP11 in both cancer diagnosis and therapy, there is a need
for deeper understanding of its mechanism and role in tumour progression. The current review focuses
on the role of MMP11 in cell signalling pathways, its expression status in various cancers, and its
potential in cancer treatment.
